OraVerse - Anesthetic Reversal

Septodont's OraVerse is the only and first FDA-approved agent for local anesthesia reversal, to rapidly reduce soft tissue numbness after dental procedures. It consists of 0.4 mg/mL phentolamine mesylate, which accelerates the process of resuming normal sensation to allow patients to continue speaking, eating, and drinking comfortably in a shorter time. OraVerse is indicated in adults and children aged 6 years and older weighing at least 15 kg. Particularly, it is recommended for people who often feel discomfort or are socially uncomfortable due to prolonged numbness after the procedure. The kit is packaged as 1 blister with 10 x 1.7 mL glass cartridges for easy use with all other systems of dental anesthesia delivery. By reversing the vasoconstricting effect of the most commonly used local anesthetics, it enhances patient satisfaction, practice experience, and patient-centered care. Moreover, for clinicians focused on speeding recovery and improving patient welfare by providing innovative options for managing patients after administration of an anesthetic agent, OraVerse qualifies as an innovative option.

Features and Benefits

• FDA-approved agent for local anesthetic reversal
• Rapid soft tissue recovery by contains phentolamine mesylate
• Enables patients to speaking, eating and function earlier after dental visits
• Pre-filled glass cartridges packaged in 10 x 1.7 mL for easy administration
• Indication for adults and children aged 6 and over (15 kg minimum weight)